ASCO21: OlympiA trial results show olaparib improves disease-free survival in high-risk, early-stage HER2-negative breast cancer with BRCA 1/2 mutations

Written by Louis Gautier, Future Science Group


The OlympiA Phase III trial recently presented results of their interim analysis at the virtual ASCO Annual Meeting (4–8 June 2021), reporting that olaparib offered a 3-year invasive disease-free survival of 85.9% in high-risk, early stage HER2-negative breast cancer patients harboring BRCA 1/2 mutations. The positive results may have implications for the standard of care in the adjuvant setting for this patient group. OlympiA is the first Phase III study to report the effect of Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in the adjuvant setting and in this early-stage, high-recurrence risk breast cancer patient group with germline BRCA1 or BRCA2...

To view this content, please register now for access

It's completely free